Abstract:Hepatitis B virus (HBV) persistently infected about 250 million people worldwide, and a curative treatment remains an unmet medical need. Among many approaches to treat chronic hepatitis B (CHB), therapeutic vaccines have been developed for two decades, but none have yielded promising results in clinical trials. Therefore, dissection of HBV clearance mechanisms during therapeutic vaccination in appropriate models, which could give rise to new curative therapies, is urgently needed. Growing evidence indicates that prolonged and intensive exposure of antigen-specific T cells to viral antigens is a major cause of T cell exhaustion, and decreases anti-HBV immunity efficacy of therapeutic vaccination. HBV X protein (HBx) is expressed at low levels, and the understanding of its immunogenicity and potential in therapeutic CHB vaccines is limited. HBV genome sequences from CHB patients were cloned into a pAAV plasmid backbone and transfected into immunocompetent mouse hepatocytes through hydrodynamic injection. Mice carrying > 500 IU/mL serum HBV surface antigen (HBs) for more than 4 weeks were considered HBV carriers mimicking human CHB and received 3 doses of weekly HBx vaccine by subcutaneous immunization. Serum HBV clearance was evaluated by monitoring serum HBs and HBV-DNA titers. Residual HBV in the liver was evaluated by western blotting for HBV core antigen. The splenic antigen-specific T cell response was quantified by a 15-mer overlapping peptide-stimulated interferon-γ enzyme-linked immunospot assay. Blood and hepatic immune cells were quantified by flow cytometric analysis. Our HBx-based vaccine induced systemic HBx-specific CD4+ and CD8+ T cell responses in HBV carrier mice and demonstrated significant HBs and HBV-DNA elimination. The protective effect persisted for at least 30 days without additional booster immunization. Different infiltrating myeloid cell subsets, each with distinctive roles during immune-mediated HBV clearance, were found in the liver of vaccinated mice. During vaccine therapy, inflammatory monocyte depletion resulted in sustained HBV clearance inhibition, whereas phagocytic monocyte-derived macrophage and Kupffer cell elimination resulted in only transient inhibition of vaccine-induced HBV clearance. We report the potential role of HBx as a major immunogen in an HBV therapeutic vaccine and the significance of a liver-infiltrating monocyte subset during hepatic viral clearance.

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model

Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers

A Single Dose of Anti-HBsAg Antibody-Encoding Mrna-Lnps Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice

A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates

HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice

Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B

Engineered Therapeutic Nanovaccine Against Chronic Hepatitis B Virus Infection.

Lentiviral Vector Encoding Ubiquitinated Hepatitis B Core Antigen Induces Potent Cellular Immune Responses and Therapeutic Immunity in HBV Transgenic Mice

A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration

A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses

Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection

Recombinant hepatitis B virus surface antigen formulated with B-type CpG oligodeoxynucleotide induces therapeutic immunity against hepatitis B virus surface antigen-expressing liver cancer cells in mice.

Lipid nanoparticle‐mediated delivery of IL‐21‐encoding mRNA induces viral clearance in mouse models of hepatitis B virus persistence

Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

Progresses on Therapeutic Hepatitis B Vaccines

Suppression of Hepatitis B Virus Antigen Production and Replication by Wild-Type HBV Dependently Replicating HBV Shrna Vectors in Vitro and in Vivo.

Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.

A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

Evaluation of Antiviral - Passive - Active Immunization ("sandwich") Therapeutic Strategy for Functional Cure of Chronic Hepatitis B in Mice.